Jay Cutler TRT: What It Would Cost a Non-Celebrity

What Jay Cutler Has Said About TRT

Jay Cutler has been direct about his hormone use in multiple public forums. On the Fouad Abiad podcast in 2021 and in subsequent Instagram Q&A sessions, Cutler stated that he uses testosterone as part of his post-competitive health maintenance, describing it as a medically supervised protocol rather than performance enhancement. This distinction matters clinically.

Decades of supraphysiologic androgen exposure during a professional bodybuilding career suppresses the hypothalamic-pituitary-gonadal (HPG) axis. The pituitary stops signaling the testes to produce testosterone naturally. Recovery of endogenous production is possible for some men after short cycles, but prolonged suppression over 20-plus years can produce permanent or near-permanent hypogonadism. Research published in the Journal of Clinical Endocrinology and Metabolism confirms that long-term anabolic-androgenic steroid use significantly suppresses gonadotropin secretion and may cause lasting hypogonadotropic hypogonadism.

Why Former Bodybuilders Often Need TRT

The HPG axis operates on a negative feedback loop. Exogenous androgens tell the hypothalamus to stop releasing gonadotropin-releasing hormone (GnRH). Less GnRH means less LH and FSH from the pituitary. Less LH means the Leydig cells in the testes produce little to no endogenous testosterone. After years at this suppressed state, the axis may not recover fully even after stopping anabolic steroids. A 2019 study in JAMA Internal Medicine (N=100 former AAS users) found that 27% of long-term AAS users had testosterone levels consistent with hypogonadism more than two years after cessation.

Inference Label: Cutler's Specific Protocol

Cutler has not released exact lab values or doses publicly. What follows is informed clinical inference based on his stated use of TRT, his age (51 as of 2025), and standard post-competitive bodybuilding endocrine patterns. Any specific dose or frequency attributed to him below is an estimate, not a confirmed figure, and is presented to illustrate what a comparable clinical protocol would look like.

The Clinical Framework for TRT Eligibility

FDA-Approved Indication

The FDA approves testosterone replacement therapy for confirmed hypogonadism: two separate morning serum total testosterone measurements below 300 ng/dL, accompanied by signs or symptoms such as reduced libido, fatigue, loss of muscle mass, or mood disturbance. The FDA label for testosterone cypionate specifies this threshold explicitly. A single low reading is insufficient for diagnosis; two are required to rule out diurnal variation.

The Endocrine Society's 2018 clinical practice guideline states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone concentrations." This guideline is available via the Journal of Clinical Endocrinology and Metabolism.

What Labs You Need Before Starting

A responsible prescriber orders the following before initiating TRT:

• Total testosterone (two morning draws, at least one week apart)
• Free testosterone (by equilibrium dialysis, not calculated, for borderline cases)
• LH and FSH (to distinguish primary from secondary hypogonadism)
• Estradiol (sensitive assay)
• Complete blood count with hematocrit
• PSA (for men over 40)
• Comprehensive metabolic panel
• Lipid panel

The American Urological Association's 2018 guideline on testosterone deficiency recommends this workup as the baseline standard of care. Skipping it is one of the most common failings at non-medical "Low T" clinics.

What a Clinical TRT Protocol Looks Like

Testosterone Cypionate: The Most Common Starting Point

Testosterone cypionate is the most widely prescribed form of TRT in the United States. It is an esterified testosterone dissolved in cottonseed oil, given as an intramuscular or subcutaneous injection. Standard physiologic replacement doses run from 100 mg to 200 mg per week, with most evidence supporting twice-weekly dosing to minimize peaks and troughs. A 2021 review in Translational Andrology and Urology confirmed that twice-weekly injections produce more stable serum levels compared to once-weekly administration.

At 100 mg twice weekly, a 10 mL vial of testosterone cypionate (200 mg/mL) lasts approximately 10 weeks. Generic testosterone cypionate costs $30, $60 per 10 mL vial at most U.S. Pharmacies with a GoodRx coupon. That is roughly $3, $6 per week in medication alone.

Transdermal and Other Delivery Options

Transdermal testosterone gel (such as AndroGel 1.62% or generic testosterone gel) is a reasonable alternative for men who avoid injections. The starting dose is 40.5 mg daily, titrated to response. Gels run $50, $150 per month at generic pricing and higher ($300, $500) for brand-name products without insurance. A 2017 NEJM study comparing delivery methods found no significant difference in testosterone-related outcomes between gel and injection at equivalent serum levels, though adherence patterns differ.

Testosterone pellets (Testopel) are implanted subcutaneously every 3 to 6 months. The procedure itself costs $300, $600 per insertion at most practices, making the annualized cost $600, $1,200 in pellet and procedure fees alone.

Ancillary Medications

Men on TRT who want to preserve fertility or testicular volume may add human chorionic gonadotropin (hCG), which mimics LH and keeps the testes active. A 2013 study in the Journal of Urology showed that hCG co-administration maintained intratesticular testosterone and sperm production in men on exogenous testosterone. Generic hCG costs $80, $150 per month.

Some men on higher-dose protocols develop elevated estradiol due to aromatization of testosterone to estrogen. An aromatase inhibitor such as anastrozole (0.5 mg twice weekly) may be added if estradiol climbs above 40 pg/mL with symptoms. Generic anastrozole costs $15, $30 per month.

Real Cost Breakdown: Non-Celebrity TRT in 2025

This section uses actual U.S. Pricing data and represents what a typical patient would pay, not what a celebrity with full concierge medical coverage might pay.

Option 1: Primary Care or Urology (Insurance-Covered)

If a patient has commercial insurance and meets the FDA hypogonadism threshold:

| Item | Estimated Patient Cost | |---|---| | Initial consultation | $30, $100 (copay) | | Baseline lab panel | $0, $150 (varies by plan) | | Testosterone cypionate 10 mL vial | $10, $40/month (generic, insurance) | | Follow-up labs (every 6 months) | $0, $75 | | Quarterly office visits | $30, $100 each | | Monthly average (all-in) | $80, $180/month |

This assumes the prescriber manages TRT within primary care or urology, which is the standard of care. The American Academy of Family Physicians supports primary care physicians prescribing TRT when hypogonadism is confirmed. See the AAFP clinical guidance here.

Option 2: Telehealth TRT Clinic (Cash-Pay)

Telehealth TRT platforms charge a subscription that typically bundles consultations, prescriptions, and sometimes lab kits. Pricing as of 2025 ranges from $100 to $250 per month. Medication is usually not included. Add $30, $60 per month for generic testosterone cypionate shipped from a compounding or retail pharmacy.

All-in monthly cost via telehealth: $130, $310.

Option 3: Concierge or Men's Health Clinic (Cash-Pay Premium)

Concierge practices offering in-person TRT management, frequent labs, and direct physician access charge $200, $500 per month for the membership alone, plus medication. This model most closely resembles what a professional athlete or celebrity would use.

All-in monthly cost: $230, $580.

Monitoring: The Part Most Men Underestimate

TRT is not a one-time prescription. Safe management requires ongoing monitoring because testosterone raises hematocrit, may affect PSA, and alters cardiovascular risk markers.

Hematocrit and Cardiovascular Risk

Testosterone stimulates erythropoiesis. Hematocrit above 54% increases blood viscosity and raises thrombosis risk. A 2023 meta-analysis in JAMA (the TRAVERSE trial, N=5,246) found that testosterone therapy in men with hypogonadism and pre-existing cardiovascular risk did not significantly increase major adverse cardiovascular events versus placebo, but did increase rates of pulmonary embolism (0.9% vs. 0.5%) and deep vein thrombosis. Hematocrit must be monitored at 3 months and every 6 to 12 months thereafter.

If hematocrit exceeds 54%, the options are dose reduction, increased injection frequency (which reduces peaks), or therapeutic phlebotomy. The Endocrine Society's 2018 guideline recommends holding TRT if hematocrit exceeds 54% until it falls below 50%.

PSA Monitoring

Men over 40 on TRT should have PSA checked at baseline, at 3 to 6 months, and annually thereafter. The American Urological Association guideline notes that a PSA rise of more than 1.4 ng/mL above baseline within the first year, or a PSA above 4 ng/mL at any point, warrants urology referral before continuing TRT.

Estradiol and Mood

Testosterone converts to estradiol via aromatase, primarily in adipose tissue. Elevated estradiol (above 40 to 50 pg/mL on a sensitive assay) can cause gynecomastia, water retention, and mood disturbance. A study in the Journal of Clinical Endocrinology and Metabolism established that estradiol is the primary hormonal determinant of sexual function in men, meaning suppressing it too aggressively with aromatase inhibitors also causes problems. The target on most clinical protocols is 20 to 35 pg/mL.

What Jay Cutler's Protocol Might Look Like (Clinical Inference)

Based on his public statements, age, and the typical post-competitive bodybuilding endocrine profile, a clinically equivalent protocol for a man in his early 50s with documented hypogonadism after long-term AAS use might include:

• Testosterone cypionate 150 to 200 mg/week (divided into twice-weekly injections)
• Estradiol monitoring with anastrozole added only if estradiol rises above 40 pg/mL with symptoms
• Hematocrit checks every 90 days
• Annual PSA and cardiovascular panel
• Possible hCG at 500 IU twice weekly if preservation of testicular function is a goal

This is a reasonable physiologic-range protocol. At 150 mg/week, most men reach total testosterone levels of 600 to 900 ng/dL, which falls within the mid-to-upper normal range (normal: 300 to 1,000 ng/dL per most laboratory reference ranges). The Endocrine Society targets the mid-normal range of 400 to 700 ng/dL for most TRT patients.

For a non-celebrity paying cash, this specific protocol would cost approximately:

• Testosterone cypionate: $40/month
• Anastrozole (if needed): $20/month
• Labs (quarterly in year one): $50, $100/month averaged
• Telehealth or physician visit: $100, $200/month
• Total: $210, $360/month

Is TRT Right for You? The Clinical Decision

TRT is appropriate when hypogonadism is biochemically confirmed and symptoms are present. It is not appropriate for normal age-related testosterone decline without symptoms, for men trying to enhance athletic performance without a medical diagnosis, or for men who want to preserve fertility without adding hCG or clomiphene. The CDC's data on testosterone use trends shows a significant increase in TRT prescriptions among men 40 to 60 from 2010 to 2020, a pattern that reflects both increased awareness and, in some cases, overdiagnosis.

A 2016 Cochrane review of TRT for late-onset hypogonadism found improvements in sexual function, mood, and lean body mass, but noted that long-term cardiovascular and prostate safety data were still limited at that time. The TRAVERSE trial (2023) has since provided the largest cardiovascular safety dataset to date.

The right starting point is a fasting morning blood draw. Get two of them before assuming you need treatment.